The mission of the Habli Laboratory of Fetal growth and Developmental Origins of Adult Disease is to deliver healthier babies, free of adult diseases. This mission drives everything we do.
Growth Restriction (IUGR) is the leading cause of perinatal morbidity and
mortality. Compelling epidemiological
and clinical studies have shown a strong association between IUGR and the
subsequent development of adult disease. The long-term effects can have
significant health and economic impacts; despite this there are currently no
therapies for IUGR.
Our lab has taken on an extremely challenging project examining
the cellular and molecular mechanisms of fetal programming in IUGR and tries to
develop targeted therapy. We developed and validated a unique surgical IUGR
mouse model that recapitulates human placental insufficiency. We are examining
a novel placental therapy leading to fetal reprogramming and alleviating the
risk of adult onset of disease such as metabolic
syndrome. We further identified potential pathways for development of adult
onset disease in growth-restricted newborn.